Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets.
about
What is synergy? The Saariselkä agreement revisitedTargeting CDK4 and CDK6: From Discovery to TherapyPerturbation biology: inferring signaling networks in cellular systemsDiscovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical ModelingCDK4 is an essential insulin effector in adipocytesNot Just a Sum? Identifying Different Types of Interplay between Constituents in Combined InterventionsCharacteristics of drug combination therapy in oncology by analyzing clinical trial data on ClinicalTrials.gov.CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.Can we unlock the potential of IGF-1R inhibition in cancer therapy?Chemical biology applied to the study of bacterial pathogens.Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.DCDB 2.0: a major update of the drug combination database.Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma.Systematic synergy modeling: understanding drug synergy from a systems biology perspective.Diverse array-designed modes of combination therapies in Fangjiomics.Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway.Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma.Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination StudiesPhosphoproteomics in translational research: a sarcoma perspective.Inhibitory effect of isothiocyanate derivant targeting AGPS by computer-aid drug design on proliferation of glioma and hepatic carcinoma cells.MLN-8237: A dual inhibitor of aurora A and B in soft tissue sarcomasThe National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases.Combinatorial Drug Testing in 3D Microtumors Derived from GBM Patient-Derived Xenografts Reveals Cytotoxic Synergy in Pharmacokinomics-informed Pathway Interactions.Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer.Using Machine Learning to Predict Synergistic Antimalarial Compound Combinations With Novel StructuresPalbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in -mutant non-small cell lung cancer
P2860
Q26782977-0FBE5E5D-1893-48F5-BE34-3BDDD920CD6FQ28082912-3CDC290B-8225-4E94-8E18-355B6175CA6AQ28537769-3F54799E-3121-4010-8B95-8EB5E675F898Q28547862-650DFC6A-FF95-47EA-9A87-0FA2E27C786FQ28585816-8943726B-16CA-4605-969D-C2E552D946D2Q30650188-A84C70AD-7379-4B83-9122-A3C5E68CD20CQ30884583-F51DCE6A-924E-40D7-8223-D3898EAC635FQ34004428-A50222BF-5C9E-4E62-B023-A6F623BB294CQ34336988-E724BBB2-78DF-470A-8A50-28DC44DE214DQ34448285-4EAB6D77-0A36-4AB1-9D39-B56C4B95A1CDQ34489987-2BF5E36E-E02E-43C2-849D-64206B3AC992Q34767007-042AF82E-85FD-4A38-BDFD-EE48DE9F6796Q35341639-442E79FC-C2DD-43F5-8574-728F61A24B66Q35777950-2A3913C1-3369-4EB6-BF1D-8C3F5428ADC0Q36123974-69255425-13CF-43A8-A1C7-0D5470C4C0C6Q37593264-A0339A19-9C80-48C0-B278-236E0A04485CQ37702556-A0370DDA-C081-4D1A-9FBB-79FB57988248Q37706527-6D3A49BB-E981-433B-9C5A-75A8A3A9D7D9Q38641329-08922227-ED30-4078-B466-52402F81B437Q38708614-89D67F48-EB66-4CA7-AC0D-8F663CFD845EQ38901686-67938C51-87CD-48F5-8745-D553331BB52BQ39990156-67BDCC64-5164-4233-BFFB-FFB6E1DC592EQ47385759-28C14519-E3C0-497D-BD8D-6F1AD4A102B4Q48321277-43096E06-2E2A-41C8-8199-F22290CF17B6Q54977613-431BAF38-B760-45FD-9369-75B99B6ADC41Q55360028-3BBE1558-F853-4DD1-807D-AC02AA5839E6Q58586909-169BF93C-3FAA-40E2-85F9-D5ADCBBE3B03Q58801080-59A99784-8678-4CD0-902D-18B162440D9D
P2860
Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Drug synergy screen and networ ...... R as synergistic drug targets.
@en
Drug synergy screen and networ ...... R as synergistic drug targets.
@nl
type
label
Drug synergy screen and networ ...... R as synergistic drug targets.
@en
Drug synergy screen and networ ...... R as synergistic drug targets.
@nl
prefLabel
Drug synergy screen and networ ...... R as synergistic drug targets.
@en
Drug synergy screen and networ ...... R as synergistic drug targets.
@nl
P2093
P2860
P50
P1433
P1476
Drug synergy screen and networ ...... 1R as synergistic drug targets
@en
P2093
Anil Korkut
Chris Sander
Evan J Molinelli
Gary K Schwartz
Jayasree S Nair
Tahir Sheikh
Xiaohong Jing
P2860
P356
10.1126/SCISIGNAL.2004014
P577
2013-09-24T00:00:00Z